Recommendations of a group of experts for the pathological assessment of tumour regression of liver metastases of colorectal cancer and damage of non-tumour liver tissue after neoadjuvant therapyRecommendations of a group of experts for the pathological assessment of tumour regression of liver metastases of colorectal cancer and damage of non-tumour liver tissue after neoadjuvant therapy

• Autores: María Luisa Gómez Dorronsoro, Ruth Vera García, Luis Ortega Medina, C. Plaza, Rosa Miquel, Mar García García, E. Díaz, M.R. Ortiz Durán, Judith Pérez Rojas, Carlos Hörndler Argarate, C. Villar Pastor, José Ramón Antúnez López, S. Pereira Gallardo, Fernando López-Rios Moreno, Ricardo González Campora
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 16, Nº. 3, 2014, págs. 234-242
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Colorectal cancer (CRC) incidence has increased during the past decades in Spain, being the first malignant tumour in incidence. Observed mortality for CRC is mainly due to liver and lung metastases. The only curative treatment is surgery; new surgical techniques and neoadjuvant treatments have increased the number of surgery candidate patients. Patients should be managed with a multidisciplinary approach that includes imaging techniques, chemotherapy, surgery and pathological assessment. As an answer to this approach, a group of pathology experts interested on CRC liver metastases aimed to review the diagnosis and prognosis of liver mestastases and developed practical recommendations for its assessment. The expert group revised the current literature and prepared questions to be discussed based on available evidence and on their clinical practise. As a result, recommendations for the assessment of tumour regression of liver metastases are proposed, which could be implemented in oncology centres allowing assessment standardisation for these patients. Prospective multi-center studies to evaluate these recommendations validity will further contribute to improve the standard care of CRC liver metastases patients.